The co-occurrence of tumor and psycho-cardiological diseases， affecting both the physical and mental aspects of patients， is a common clinical condition that is closely related to tumor treatment and prognosis. Exploring its underlying mechanism and treatment methods can bring new ideas and strategies for clinical treatment. It is believed that heart-kidney yang deficiency is one of the common core mechanisms of psycho-cardiological diseases. Stagnation of heat and toxins is a core mechanism for tumor formation and metastasis. Additionally， cancer and drug toxicity contribute to the development of psycho-cardiological disease by impairing lung circulation. Cancerous toxins can damage the blood vessels， resulting in a diminished vitality in the heart of blood vessels. Simultaneously， lung qi failing in dispersing impairs the downward movement and causes stagnation in the heart of spirit . This process ultimately leads to the development or exacerbation of psycho-cardiological diseases. The author explores the diagnosis and treatment approach based on the “diagnosing and treating diseases according to syndroms” concept， focusing on related syndrom identification and treatment. The process begins with pattern identification， followed by comprehensive analysis of data gained by four diagnostic methods to clearly understand the core pathogenesis and basic treatment principles. After pattern identification， the focus shifts to recognizing the disease and providing additional evidence to support the diagnosis. Special attention is paid to adjusting the use of medication based on the disease's characteristics. This approach aims to achieve precise treatment for tumors and psycho-cardiological diseases， reducing the side effects of multiple medications， therefore to provide guidance for clinical application.

Immune checkpoint inhibitors （ICIs） have shown good efficacy in tumor treatment and have changed the landscape of tumor treatment. However， some patients treated with ICIs have not only failed to achieve the desired therapeutic effect， but also developed an atypical response pattern of abnormally accelerated tumor growth， namely hyperprogressive disease （HPD）. The pathogenesis of HPD is still unclear and it is difficult to diagnose， which poses a challenge for clinical identification and treatment decisions. Exploring the underlying mechanism of HPD is important to improve the effect of immunotherapy. Based on the theory of "Yang deficiency and toxic knot"， this paper discussed the mechanism of HPD in immunotherapy from the perspective of "spleen and kidney Yang deficiency and hefty toxic pathogens". It was concluded that the inactivation of p53 oncogene and immunosuppressive microenvironment were the manifestations of the deficiency of healthy qi in the body and declined yang in the spleen and kidney， serving as an important basis for the occurrence of HPD. Adverse reactions caused by ICIs belong to the category of "drug toxicity". The occurrence and development of murine double minute 2 （MDM2）/murine double minute 4 （MDM4） activation， epidermal growth factor receptor （EGFR） mutation， and tumor inflammatory microenvironment are the manifestations of the hyperactivity of pathogenic Qi， conflict of cancer toxicity and drug toxicity， and being hefty by virtue of deficiency， which can promote the abnormal proliferation of tumor cells， and they are the core pathogenic elements of HPD and are closely related to disease prognosis. In terms of treatment， under the guidance of the theory of "five views on differentiation and treatment" （time-space view， core view， symptom view， precision view， and disease-before-onset view）， which was summarized according to the clinical practice of this research team， this paper， taking the prevention and treatment of HPD as the entry point， formulated traditional Chinese medicine （TCM） compounds to reinforce healthy Qi and warm Yang and realize the dynamic management of the whole spatiotemporal cycle， and removed toxins and resisted cancer to realize the all-round systemic intervention of the specimen. Additionally， targets were enriched in the macro-clinical manifestations and microscopic pathological changes of HPD to improve the targeting of drug selection and the precision of prevention and treatment， giving full play to the unique therapeutic advantages of TCM， and providing new ideas for the clinical application of TCM in the prevention and treatment of HPD.